October 23, 2013
Shionogi and Nipro Corporation announced on October 22 that the two companies have entered into a copromotion deal in Japan for Shionogi’s anti-influenza treatment Rapiacta (peramivir). Rapiacta, licensed from BioCryst Pharmaceuticals of the US to Shionogi, was launched in Japan...read more